Edition:
United States

argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

74.05USD
4:00pm EDT
Change (% chg)

$1.36 (+1.87%)
Prev Close
$72.69
Open
$74.76
Day's High
$74.76
Day's Low
$72.14
Volume
48,556
Avg. Vol
51,615
52-wk High
$103.00
52-wk Low
$22.21

Latest Key Developments (Source: Significant Developments)

Argenx Raises About $300.6 Mln In Gross Proceeds In U.S. Public Offering
Tuesday, 18 Sep 2018 08:45pm EDT 

Sept 18 (Reuters) - argenx SE ::REG-ARGENX RAISES APPROXIMATELY $300.6 MILLION IN GROSS PROCEEDS IN A U.S. PUBLIC OFFERING.ARGENX SE -PRICING OF AN UNDERWRITTEN PUBLIC OFFERING IN UNITED STATES AND AN OFFERING IN EUROPE ONLY TO QUALIFIED INVESTORS.ARGENX SE -PRICING OFFERED WITH ANTICIPATED GROSS PROCEEDS TOTALLING ABOUT $300.6 MILLION FROM SALE OF 3,475,000 ADSS AT $86.50 PER ADS.ARGENX SE -EACH OF ADSS OFFERED REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE.  Full Article

Argenx Announces Launch Of Proposed Public Offering In The U.S.
Monday, 17 Sep 2018 04:20pm EDT 

Sept 17 (Reuters) - Argenx Se ::ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES.COMMENCED UNDERWRITTEN U.S. PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND AN OFFERING OF ADSS IN EUROPE ONLY TO QUALIFIED INVESTORS.ADS FOR APPROXIMATELY $300 MILLION.EACH OF ADSS OFFERED IN OFFERING REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE.ALL OF THE ADSS IN THE PROPOSED OFFERING ARE TO BE SOLD BY ARGENX.  Full Article

Argenx Says Abbvie Exercises Exclusive Option To License Argx-115
Wednesday, 22 Aug 2018 02:00am EDT 

Aug 22 (Reuters) - ARGENX SE ::REG-ARGENX ANNOUNCES THAT ABBVIE HAS EXERCISED ITS EXCLUSIVE OPTION TO LICENSE ARGX-115, A NOVEL IMMUNO-ONCOLOGY ANTIBODY.EXERCISE BY ABBVIE OF ITS EXCLUSIVE LICENSE OPTION TO DEVELOP AND COMMERCIALIZE ARGX-115.ARGENX AND ABBVIE ENTERED INTO AN OPTION AND LICENSE AGREEMENT FOR ARGX-115 IN APRIL 2016.  Full Article

Argenx ‍Announces Expansion Of Its Pipeline
Thursday, 22 Mar 2018 02:29am EDT 

March 22 (Reuters) - ARGENX NV ::‍ANNOUNCES EXPANSION OF ITS PIPELINE WITH ADDITION OF COMPLEMENT-TARGETED ARGX-117 FOR TREATMENT OF SEVERE AUTOIMMUNE DISEASES​.  Full Article

Photo

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.